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http://dx.doi.org/10.1016/j.jmii.2012Background: The rising incidence of non-albicans Candida (NAC) infection has been associated
with a potentially adverse outcome for patients with candidemia. However, categorizing
various species causing candidemia into a single NAC group might lead to inappropriate conclu-
sions due to heterogeneity in species. Thus we examined the associated factors among patients
with candidemia caused by different species.
Methods: This retrospective study was conducted at a tertiary medical center in Taiwan from
2006 to 2009. Mortality rate, demographic and clinical characteristics, albumin levels, and
severity scores of acute illness of patients at the onset of candidemia were analyzed.
Results: A total of 447 episodes among 418 patients were included for analysis. The overall
30-day crude mortality was 48.2%, with no significant difference between C. albicans and
NAC candidemia, but apparently C. parapsilosis candidemia was associated with a lower
mortality rate. Time to positivity for yeast was significantly different between species.
Compared with infection involving C. albicans, more frequent use of total parenteral nutrition,Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, No. 201, Section 2,
v.tw (F.-D. Wang).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
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464 L.-Y. Chen et al.lower Sequential Organ Failure Assessment score and higher albumin levels were observed for
C. parapsilosis candidemia.
Conclusion: Identifying associated factors for each speciesmay beamoreeffective approach than
single NAC grouping. Time to positivity may be a hint for treatment guidance in candidemia. More
frequent use of total parenteral nutrition and less virulent nature were noted for C. parapsilosis
candidemia.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Invasive fungal infections in hospitalized patients are
associated with significant morbidity and mortality rates.1
Candida species are the most common cause of invasive
fungal infections, accounting for approximately 15% of all
hospital-acquired infections and >72% of nosocomial fungal
infections.1,2 The mortality rate associated with invasive
candidiasis has been reported to be as high as 40% to 50%.3,4
Furthermore, candidemia is the fourth most common cause
of nosocomial bloodstream infections in the United States
and is prevalent in much of the developed world.1,5
The rising incidence of Candida infections, including
non-albicans candidemia, has been well described through
several epidemiological studies since the 1980s.6e8 The
increasing incidence of Candida infections has been asso-
ciated with an increased use of broad-spectrum antibac-
terial agents, central venous catheters, and implantable
prosthetic devices, as well as increased receipt of paren-
teral nutrition, renal replacement therapy, and immuno-
suppressive agents.9e11
Candida albicans remains the primary cause of invasive
candidiasis according to the ARTEMIS DISK global antifungal
surveillance study.12 However, the emergence of non-albi-
cans Candida (NAC) infections has become a major problem
due to increased exposure to antifungals for prophylactic use
in patients receiving bone marrow transplantation and for
pre-emptive treatment of critical patients.13 Risk factors for
non-albicans candidemia, which have been studied exten-
sively in different clinical settings, include recent antifungal
exposure, gastrointestinal surgery, increased patient age,
and intravenous drug use relative to C. albicans can-
didemia.14e17 Potential fluconazole resistance and delayed
treatment associated with C. glabrata and C. krusei infec-
tions may be related to an increased incidence of an adverse
outcome. However, half of the NAC species, including
C. tropicalis and C. parapsilosis, continued to show
susceptibility to fluconazole. As such, categorizing different
Candida species into a single NAC group may lead to inef-
fective treatment.
The aim of this study was to analyze associated factors
and clinical characteristics of patients with candidemia
caused by different Candida species and elucidate the
differences among NAC species compared with C. albicans
candidemia. In addition to underlying diseases, invasive
procedures, and mortality, the significance of two scoring
systems for determining acute illness severity as well as
time to positivity (TTP) of blood cultures for yeast were
also explored.Materials and methods
Patient identification and data collection
This retrospective study examined patients with positive
blood culture for yeast, as determined using microbiolog-
ical laboratory findings, at a 2900-bed tertiary medical
center from January 1, 2006, to December 31, 2009. Blood
cultures were collected using standard sterile procedures
via peripheral vessels. Culture results were considered true
candidemia when the positive blood culture was sampled
via the peripheral vessels for at least one set and the
patient was associated with concomitant symptoms and
signs of systemic inflammatory response syndrome.18
Infection control staff identified each episode as true
candidemia by reviewing patient medical records. Patient
characteristics and information regarding comorbidities,
length of hospital stay, number and types of invasive
procedures, TTP for yeast, final reports of species identi-
fication, and 30-day crude mortality were collected for
analysis. The acute physiological and chronic health eval-
uation II (APACHE II)19 and sequential organ failure assess-
ment (SOFA) scores20 were used to determine the severity
of acute illness.
Patients were excluded from participating in the study if
they were younger than 16 years, were identified as having
two or more Candida species at the same time, or had
another episode diagnosed within 30 days. Patients with
two episodes of candidemia diagnosed 30 days apart were
considered as having acquired another infectious episode
unless a failed primary focus eradication was identified.
Microbiological identification and antimicrobial
susceptibility
Pathogens were initially isolated from blood cultures using
the BacT/ALERT 3D system (bioMe´rieux, Marcy l’E´toile,
France) during the study period. Species identification and
antifungal agent susceptibility was determined using stan-
dard biochemical testing with an ATB ID 32C kit (bio-
Me´rieux, Hazelwood, MO, USA) and using the Vitek 2 system
with the ID-YST Card (bioMe´rieux). Susceptibility results
were interpreted based on species-specific criteria updated
in 2010 by the Clinical Laboratory and Standards Institute.21
Definition
Underlying comorbidities were identified based on previous
medical records with clear documentation. Catheter-related
Table 1 Demographics and clinical characteristics of patients
with candidemia
Variable Overall n Z 447
Age (years) 68  16
Male sex 300 (67.1)
Onset at ICUs 157 (35.1)
14-d mortality 161 (36.0)
30-d mortality 215 (48.1)
Precandidemia LOS (d) 40  76
LOS (d) 77  110
TTP for yeast (h) 61.9  21.8
APACHE II score 24.6  8.8









Organ transplantation 6 (1.3)
Liver cirrhosis 23 (5.1)
Pancreatitis 33 (7.4)
Solid tumor 207 (46.3)
Hematological malignancy 31 (6.9)
Collagen vascular disease 15 (3.4)
Conditions within previous 30 d
ICU admission 232 (51.9)
Operation 145 (32.4)
Antacid use 296 (66.2)
Chemotherapy 73 (16.3)
Immunosuppressive therapy 69 (15.4)
Colonization 198 (44.3)






Nasogastric tube usage 312 (69.8)
Mechanical ventilation 186 (41.6)
Nontunneled CVCs 295 (66.1)
Removal of nontunneled CVCs 214 (72.8)
Tunneled CVCs 150 (33.6)
Removal of tunneled CVCs 46 (30.7)
Arterial line 129 (28.9)
Parenteral nutrition 221 (49.4)
TPN 122 (27.3)
PPN 163 (36.5)
Urinary catheters 238 (53.2)
Surgical drainage devices 130 (29.1)
Previous antifungal agents exposure 39 (9.3)
Concurrent bacteremia 79 (17.7)
Data are n (%) or mean  SD unless otherwise indicated.
CAD Z coronary artery disease; CHF Z congestive heart failure;
COPD Z chronic obstructive pulmonary disease; CRI Z chronic
renal insufficiency; CVAZ cerebrovascular accident; CVCZ central
venous catheter; DM Z diabetes mellitus; ESRD Z end stage renal
disease; ICU Z intensive care unit; LOS Z length of hospital stay;
PPN Z peripheral parenteral nutrition; SD Z standard deviation;
TPN Z total parenteral nutrition; TTP Z time to positivity.
Different Candida species in patients with candidemia 465infectionswere identifiedusing semiquantitative tipcultureof
indwelling catheters with growth of 15 colonies identical to
the species identified from the peripheral blood culture.
Chronic renal insufficiency was identified based on serum
creatinine levels>1.5mg/dLoranestimatedserumcreatinine
clearance<30mL/min/1.73 m2 for>6months, and end stage
renal diseasewas defined as serum creatinine levels>6.0mg/
dL or estimated serum creatinine clearance <10 mL/min/
1.73 m2 for >6 months. Antacid use included only usage of
proton-pump inhibitors or H2 channel blockers for 3 days.
Immunosuppressive therapy was defined at immunosuppres-
sant or corticosteroid use at a dosage equivalent to predniso-
lone 20 mg per day for at least 3 days. Patients with
neutropenia included those with absolute neutrophil counts
of <1.0  109 cells/L with candidemia. Patients with
thrombocytopenia included those with platelet counts
of <100,000  109 cells/L with candidemia. Peripheral pare-
nteral nutrition only included those patients receiving
administration of a lipid-containing formulation. Colonization
was defined as positive growth of yeast from at least one
surveillance site.22
Statistical analysis
The Chi-square test or Fisher’s exact test was used for
categorical comparisons of data. Differences between
continuous variables among the different Candida species
were analyzed by analysis of variance (ANOVA) with posthoc
tests. A p value <0.05 was considered statistically signifi-
cant. Variables with a p value <0.1 according to univariate
analysis were included in a logistic regression model to
identify the most important risk factors. All analyses were
performed using the SPSS for Windows, version 17.0 (SPSS,
Inc., Chicago, IL, USA).
Results
A total of 485 episodes of candidemia were recorded during
the study period. Thirty-eight episodes were excluded due
to double species infection or incomplete clinical data
collection. A total of 447 episodes occurring in 418 patients
were included for analysis. The demographic and clinical
characteristics of these patients are shown in Table 1.
Overall 30-day crude mortality was 48.2%. The 30-day
mortality among patients with C. albicans and NAC candi-
demia was 51.9% and 42.9% respectively (p Z 0.058).
Candida albicans was the most common pathogen iden-
tified in this study (57.7%), followed by C. tropicalis
(15.0%), C. parapsilosis (13.0%), and C. glabrata (8.3%). The
final identification of yeast in case of candidemia is shown
in Table 2. A total of 420 episodes with final identification
of one of the four aforementioned common species were
included for further analysis. Demographic characteristics,
clinical conditions, and comparison by univariate analysis
among the different Candida species are summarized in
Table 3. Although the mortality rates had no significant
difference between C. albicans and NAC candidemia,
apparently C. parapsilosis candidemia was associated with
a lower mortality rate.
Table 2 Identification of yeast species
Species identification Number of isolates (%)
C. albicans 258 (57.7)
C. tropicalis 67 (15)
C. parapsilosis 58 (13)
C. glabrata 37 (8.3)
Others 27 (6)







466 L.-Y. Chen et al.In the logistical regressionmodel of multivariate analysis,
variables including SOFA scores, albumin level, TTP for
yeast, and use of total parenteral nutrition (TPN) achieved
statistical significance among the three NAC species
compared with C. albicans (Table 4). Compared with that of
C. albicans, a longer TTP for yeast was more frequently
observed in C. parapsilosis and C. glabrata, while a shorter
TTP was observed C. tropicalis. A lower SOFA score, higher
albumin level and more prevalent usage of TPN were asso-
ciated with C. parapsilosis candidemia, while less associa-
tion with TPN was noted for C. tropicalis candidemia.Table 3 Univariate analysis of risk factors among the four com
Variable C. albicans C. trop
n Z 258 n Z 67
Age (years) 70  16 67  15
30-day mortality 134 (52) 39 (58)
TTP for yeast (hours) 58.4  18.2 50.6 
APACHE II score 25.2  8.6 26.0 
SOFA score 6.9  4.7 7.9  4
Underlying comorbidities
Hematological malignancy 12 (5) 7 (10)
Conditions within previous 30 days
ICU admission 127 (49) 41 (61)
Antacid use 165 (64) 52 (78)
Colonization 119 (46) 38 (57)
Albumin (gm/dl) 2.69  0.62 2.60 
Thrombocytopenia 127 (49) 46 (69)
Procedures
Nasogastric tube usage 185 (72) 46 (69)
Arterial line 74 (29) 19 (28)
TPN 71 (28) 12 (18)
Fluconazole susceptibility rate 237 (97) 59 (92)
MIC50 (mg/L) <1 <1
MIC90 (mg/L) <1 2
MIC range (mg/L) <0.25e>128 0.25e>
* p < 0.05.
Data are n (%) or mean  SD unless otherwise indicated.
ICU Z intensive care unit; MIC Z minimal inhibitory concentration
TTP Z time to positivity.Discussion
Overall 30-day crude mortality in patients with candidemia
was 48.2%, which was not significantly different from
C. albicans and other NAC groups. Although Moran et al.
reported that an increased mortality rate and cost was
noted in an adult population with NAC candidemia in the
USA,14 several other studies failed to identify a difference
in the mortality rate between patients with C. albicans or
NAC candidemia.17,23,24 Oversimplifying categorization
method for different species into a single NAC group may
explain the different conclusions among these studies and
may indicate differences in both incidence and species
distribution between geographic regions and institu-
tions.6,8,25 As described in the ARTEMIS DISK surveillance
study, the distribution of C. glabrata with potential fluco-
nazole resistance was less common in the Asia-Pacific
region (12.6%) than in North America (21.1%).12 The fluco-
nazole susceptibility rate among Candida species presented
here is similar to that reported in the ARTEMIS DISK
surveillance study. Thus, identifying invasive candidiasis on
an individual basis would enable more precise conclusions
in different clinical settings.
The TTP for yeast showed significant differences
between species before final species identification. The
TTP for yeast was similar to the natural growth speed of
each Candida species, as described previous reports.26e28 A
recent report by Ben-Ami et al. also revealed the TTP to bemon Candida species
icalis C. parapsilosis C. glabrata p
n Z 58 n Z 37
63  16 72  14 0.011*
15 (26) 15 (41) 0.001*
13.9 71.3  26.9 90.7  36.5 <0.001*
8.4 20.8  7.7 26.0  9.1 0.002*
.7 4.7  4.1 7.2  4.7 0.001*
7 (12) 2 (5) 0.049*
26 (45) 25 (68) 0.049*
35 (60) 28 (76) 0.076
15 (26) 22 (60) 0.002*
0.64 2.91  0.54 2.53  0.59 0.006*
20 (35) 18 (49) 0.002*
32 (55) 30 (82)* 0.035*
12 (21) 17 (46) 0.068
25 (43) 10 (27) 0.019*




; SD Z standard deviation; TPN Z total parenteral nutrition;
Table 4 Multivariate analysis of the relative risk among different species compared with C. albicans
Variable OR (95% CI) in C. tropicalis OR (95% CI) in C. parapsilosis OR (95% CI) in C. glabrata
SOFA scores 1.06 (0.99e1.14) 0.90 (0.84e0.98)* 0.97 (0.88e1.07)
Albumin 1.14 (0.68e1.93) 2.55 (1.33e4.88)* 0.80 (0.38e1.70)
TTP for yeast 0.96 (0.94e0.98)* 1.04 (1.02e1.05)* 1.06 (1.04e1.07)*
Use of TPN 0.43 (0.20e0.92)* 3.01 (1.46e6.23)* 2.22 (0.82e6.03)
* p < 0.05.
TTP Z time to positivity; TPN Z total parenteral nutrition.
Different Candida species in patients with candidemia 467an early indicator for catheter-related candidemia.26 This
information may be used to guide antifungal therapy before
final species identification in patients with candidemia who
are in critical condition. Further studies examining the
clinical significance of TTP for yeast are necessary.
Between the two scoring systems used to determine the
severity of acute illness, the SOFA score is easier to
determine in clinical field and showed more statistical
significance in multivariate analysis compared to the
APACHE II score. A linear association was observed between
the SOFA score and APACHE II score according to the
logistical linear regression model (p < 0.001). However,
unlike APACHE III, no further age grading was available for
those older than 65 years, and no dynamic grading was
available for urine output in the APACHE II scoring
system.19,29 Thus the APACHE II score should show a smaller
difference than the SOFA score among species examined in
our study population.
Among patients with C. parapsilosis candidemia, a lower
SOFA score, higher albumin level and more frequent TPN
usage were common associated clinical characteristics.
These factors may suggest a less virulent nature for the
C. parapsilosis infection as a previous report in an animal
model.30 The slow growing rate and lower fluconazole
nonsusceptibility percentage of C. parapsilosis may explain
the lower patient mortality rate, lower APACHE II and SOFA
scores, and higher albumin level determined through
univariate analysis.31 Similar to the results of previous
studies, C. parapsilosis candidemia was associated with
a more prevalent TPN usage.13,32 Although the virulence of
non-albicans species remains unclear, biofilm formation
and parenteral hyperalimentation may be risk factors for
identifying C. parapsilosis candidemia in susceptible hosts.
A less significant association with TPN usage was noted for
C. tropicalis candidemia.
A lower mortality rate was observed in patients with
C. glabrata candidemia compared to those with C. albicans
candidemia. The first line antifungal agent for treating
candidemia was 400 mg/day fluconazole at a dosage of
after an 800 mg loading dosage at our hospital during the
study period, rather than treatment with echinocandin or
amphotericin B. Similar to the fluconazole-nonsusceptible
rate, 30-day crude mortality in patients with C. glabrata
candidemia was 40.5%, which is not as high as that reported
previously (range 40% to 70%).5,33,34 Moreover, several
studies have indicated that candidemia caused by C. glab-
rata is not associated with an increase in mortality or
length of hospital stay, but it is associated with higher
treatment cost for antifungal therapy.7,35,36 Therefore,
C. glabrata virulence may not be as toxic as expected
because of its slow growth rate, and the adverse outcomerelated to C. glabrata candidemia may be related to an
increased probability of azole-resistance, underlying
multiple comorbidities,25,28,35,37 or higher prevalence of
intensive care unit admission. However, a healthy worker
effect may exist due to the retrospective design of this
study for the decreased mortality rate among patients with
C. glabrata candidemia. Further in vitro studies of
C. glabrata are necessary to establish the clinical signifi-
cance of this infection and to determine virulence factors
in addition to intrinsic fluconazole-nonsusceptiblity.
In conclusion, categorizing different Candida species
into a single NAC group may not be a sufficient approach for
determining treatment due to the heterogeneity that exists
among species and to different species distributions among
institutes and geographic areas. Identifying associated
factors for each species may be a better approach than
using simple NAC grouping, while the TTP for yeast may be
helpful in guiding antifungal therapy measures.
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